tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Ufp Technologies (UFPT), Apyx Medical (APYX) and Wuxi Biologics (Cayman) (OtherWXIBF)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ufp Technologies (UFPTResearch Report), Apyx Medical (APYXResearch Report) and Wuxi Biologics (Cayman) (WXIBFResearch Report) with bullish sentiments.

Ufp Technologies (UFPT)

In a report issued on January 17, Jaeson Schmidt from Lake Street maintained a Buy rating on Ufp Technologies, with a price target of $31.00. The company’s shares closed last Monday at $161.24.

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 10.4% and a 51.0% success rate. Schmidt covers the Technology sector, focusing on stocks such as Lightpath Technologies, Benchmark Electronics, and SoundThinking Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ufp Technologies with a $31.00 average price target.

See the top stocks recommended by analysts >>

Apyx Medical (APYX)

In a report issued on January 17, Matt Hewitt from Craig-Hallum maintained a Buy rating on Apyx Medical, with a price target of $9.00. The company’s shares closed last Monday at $2.11, close to its 52-week low of $1.41.

According to TipRanks.com, Hewitt is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.8% and a 41.6% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Streamline Health Solutions, Champions Oncology, and BioLife Solutions.

Apyx Medical has an analyst consensus of Moderate Buy, with a price target consensus of $5.17, representing a 151.0% upside. In a report issued on January 8, Lake Street also maintained a Buy rating on the stock with a $3.00 price target.

Wuxi Biologics (Cayman) (WXIBF)

CMB International Securities analyst Jill Wu maintained a Buy rating on Wuxi Biologics (Cayman) on January 17 and set a price target of HK$39.65. The company’s shares closed last Monday at $3.60, close to its 52-week low of $3.37.

According to TipRanks.com, Wu ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.4% and a 21.1% success rate. Wu covers the Healthcare sector, focusing on stocks such as CSPC Pharmaceutical Group, Innovent Biologics, and BeiGene.

Wuxi Biologics (Cayman) has an analyst consensus of Strong Buy, with a price target consensus of $6.08, implying a 69.0% upside from current levels. In a report issued on January 11, CLSA also upgraded the stock to Buy with a HK$37.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on UFPT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles